Search | Clinical Trials Finder

Conditions: Edematous, Synovitis, Foreign Body Reaction, Osteolysis
Interventions: Placebo, Apatone®B; Drug
Lead sponsor: IC-MedTech Corporation; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Hallucinations, Auditory, Psychosis
Interventions: Rivastigmine Transdermal System, Scopolamine, Placebo Patch; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: End Stage Renal Disease, Chronic Kidney Disease
Interventions: TRF (Tocotrienol-rich-fraction), Placebo; Dietary Supplement
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Major Depressive Disorder
Interventions: Transdermal estradiol, Progesterone, Transdermal placebo patch, placebo capsule; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Cognitive Impairment Associated With Schizophrenia
Interventions: Nicotine patch, MK-4334, Placebo patch, Placebo capsule; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Long Beach, California • Marlton, New Jersey

Conditions: Papulopustular Rosacea
Interventions: DFD-29, Doxycycline, Placebo; Drug
Lead sponsor: Journey Medical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 27
States / cities: Rogers, Arkansas • Cerritos, California • Fremont, California + 21 more

Conditions: Tobacco Use Disorder
Interventions: ModafinilNicotine Replacement Therapy, Modafinil; Drug
Lead sponsor: Catherine Martin, MD; Other
Eligibility: 16 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Cigarette Smoking
Interventions: D-cycloserine, Nicotine Replacement Therapy (patch), Smoking Cue Exposure, Progressive Muscle Relaxation, Placebo; Drug · Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Nicotine Dependence, Smoking Cessation
Interventions: EVP-6124, Placebo Capsule, NicoDerm Patch (Active), NRT Patch (Placebo), Brief Supportive and Behavioral Treatment; Drug · Behavioral
Lead sponsor: A. Eden Evins; Other
Eligibility: 18 Years to 65 Years
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Relapsing Multiple Sclerosis
Interventions: Remibrutinib, Teriflunomide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 52
States / cities: Phoenix, Arizona • Tucson, Arizona • Fort Smith, Arkansas + 47 more

Conditions: Relapsing Multiple Scelrosis
Interventions: Ofatumumab subcutaneous injection, Teriflunomide-matching placebo capsules, Teriflunomide capsule, Matching placebo of ofatumumab subcutaneous injections; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 955 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 59
States / cities: Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 51 more

Conditions: Skin Infections, Bacterial
Interventions: Retpamulin Ointment, 1%, Linezolid; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 2 Months and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 53
States / cities: Anniston, Alabama • Birmingham, Alabama • Bentonville, Arkansas + 46 more

Conditions: Memory Loss, Cognitive Changes, Postmenopausal Symptoms
Interventions: Estradiol oral capsule, transderman estrogen patch, trasdermal placebo patch, placebo oral capsule; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 45 Years to 80 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Menopause, Arteriosclerosis
Interventions: Conjugated equine estrogens 0.45 mg/day, Transdermal estradiol, 50 mcg/day, Micronized progesterone, 200 mg/day x 12 d/month, CEE , progesterone, estradiol patch or placebo for each, CEE, progesterone, transdermal patch or the placebo; Drug
Lead sponsor: Kronos Longevity Research Institute; Other
Eligibility: 42 Years to 58 Years · Female only
Enrollment: 728 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2012
U.S. locations: 9
States / cities: Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 6 more

Conditions: Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
Interventions: Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo; Drug · Other
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 6 Years to 28 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Seattle, Washington

Conditions: Perimenopausal Disorder, Stress, Emotional
Interventions: Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release, Placebo Patch, Progesterone Capsule, Placebo Oral Capsule; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Chapel Hill, North Carolina

Conditions: Relapsing Multiple Sclerosis
Interventions: Remibrutinib, Teriflunomide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,007 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 50
States / cities: Phoenix, Arizona • Hanford, California • Los Angeles, California + 42 more

Conditions: Suicidal Ideation
Interventions: Estradiol Transdermal Patch 0.1 mg/24 hrs, Oral Micronized Progesterone 200mg, Inactive Clear Patch, Placebo capsule; Drug
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Relapsing Multiple Sclerosis
Interventions: Ofatumumab subcutaneous injection, Teriflunomide-matching placebo capsules, Teriflunomide capsule, Matching placebo of ofatumumab subcutaneous injections; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 930 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 56
States / cities: Phoenix, Arizona • Berkeley, California • Fullerton, California + 50 more

Conditions: Oral Leukoplakia
Interventions: Pioglitazone hydrochloride, placebo, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 11
States / cities: Birmingham, Alabama • Iowa City, Iowa • Boston, Massachusetts + 6 more

Conditions: Osteoarthritis, Hip
Interventions: Periarticular injection (Deep injection), Periarticular injection (Superficial injection), Bupivacaine, Placebo; Procedure · Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 50 Years to 75 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Smoking Cessation
Interventions: Meclizine, Nicotine Patch, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Charlotte, North Carolina • Durham, North Carolina • Raleigh, North Carolina + 1 more

Conditions: Psoriasis
Interventions: Acitretin 25Mg Oral Capsule, Excimer laser, Tazarotene 0.1% Gel,Top, Sham excimer laser; Drug · Device
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Acne Vulgaris
Interventions: CD2475/101 40 mg, Doxycycline 100 mg, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years and older
Enrollment: 662 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 31
States / cities: Hot Springs, Arkansas • Los Angeles, California • Denver, Colorado + 25 more

Search by objective public record fields.

Double-Blinded Clinical Trial Using Apatone®B for Symptomatic Postoperative Total Joint Replacements

Toward a Computationally-Informed, Personalized Treatment for Hallucinations

Palm Tocotrienols in Chronic Hemodialysis (USA)

Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)

A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.

Safety of Combining Modafinil and Nicotine Replacement Therapy in Treating Nicotine Dependent Adolescents

Effects of Nicotine Replacement Therapy and D-cycloserine on Nicotine Treatment Seekers

A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA

Aging and Estrogen on Cortical Function

Kronos Early Estrogen Prevention Study (KEEPS)

Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

The Menopause Transition: Estrogen Variability, Stress Reactivity and Mood

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

Pioglitazone for Oral Premalignant Lesions

Minimal Opioid Use After Total Hip Replacement (THR)

Meclizine as a Potential Smoking Cessation Treatment

Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis

Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris